Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus.

Sascha HoppeLydia Meder Florian GebauerRoland T UllrichThomas Zander Axel Maximilian Hillmer Reinhard Buttner Patrick Sven Plum Julian PuppeWolfram MalterAlexander Quaas

Published in: Cancers (2022)

Our data suggest that sacituzumab govitecan is a new therapy option in esophageal adenocarcinoma and the TROP2 expression in irinotecan-naïve EAC correlates with the extent of treatment response by sacituzumab govitecan. TROP2 is emerging as a predictive biomarker in completely TROP2-negative tumors. This should be considered in future clinical trials.

Keyphrases

cell surface
clinical trial
squamous cell carcinoma
poor prognosis
locally advanced
electronic health record
current status
randomized controlled trial
machine learning
binding protein
radiation therapy
data analysis
phase ii
deep learning
rectal cancer
artificial intelligence
double blind